Sanofi SNY
NASDAQ SNY
$48.39 +0.02 (+0.04%)
At close: Nov 16, 2026 · 4:00 PM EST

Sanofi (SNY) Net Income Attributable to Noncontrolling Interests (2009 - 2026)

Updated

Sanofi's Net Income Attributable to Noncontrolling Interests came in at $55.22 million for Q3 2026, up 687.3% from $7.01 million a year earlier and up 39.7% from the prior quarter.

Analysis

Sanofi (SNY) Net Income Attributable to Noncontrolling Interests (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 30, 2026, Sanofi reported Net Income Attributable to Noncontrolling Interests of $109.91 million, up 136.6% year-over-year; for FY2025, it was $42.93 million, down 31.6% from FY2024.

  • Net Income Attributable to Noncontrolling Interests carries a five-year compound annual growth rate of 0.9% (FY2020 to FY2025).
  • Going back by year, Net Income Attributable to Noncontrolling Interests was $62.78 million in FY2024 (+61.2%), $38.94 million in FY2023 (-67.3%), $119.1 million in FY2022 (+79.7%) and $66.27 million in FY2021 (+61.2%).
  • The Q3 2026 figure represents the highest quarterly Net Income Attributable to Noncontrolling Interests since Q4 2022.
  • Year-over-year, Net Income Attributable to Noncontrolling Interests increased in four of the last seven quarters, with growth averaging 191.3%.
  • The fastest year-over-year change in Net Income Attributable to Noncontrolling Interests over five years came in Q2 2026 (growth of 772.8%), and the weakest in Q3 2022 (a decline of 90.1%).
  • Business Quant data shows SNY's Net Income Attributable to Noncontrolling Interests at $39.52 million (Q2 2026), $7.02 million (Q1 2026) and $8.15 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 2.00 Mn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -1.00 Mn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 10.00 Mn
10 Sanofi 59.05 Bn 29.25 Bn 33.35 Bn 55.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 55.22 Mn
Jun 30, 2026 39.52 Mn
Mar 31, 2026 7.02 Mn
Dec 31, 2025 8.15 Mn
Sep 30, 2025 7.01 Mn
Jun 30, 2025 4.53 Mn
Mar 31, 2025 22.09 Mn
Dec 31, 2024 12.82 Mn
Sep 30, 2024 31.85 Mn
Jun 30, 2024 4.31 Mn
Mar 31, 2024 14.12 Mn
Dec 31, 2023 -3.23 Mn
Sep 30, 2023 14.15 Mn
Jun 30, 2023 13.07 Mn
Mar 31, 2023 15.03 Mn
Dec 31, 2022 58.15 Mn
Sep 30, 2022 3.02 Mn
Jun 30, 2022 64.02 Mn
Mar 31, 2022 -7.86 Mn
Dec 31, 2021 11.44 Mn
API Access

Sanofi Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SNY&period=max&api_key=YOUR_API_KEY